Article ID Journal Published Year Pages File Type
10964873 Vaccine 2015 8 Pages PDF
Abstract
HD is expected to achieve significant reductions in influenza-related morbidity and mortality. Further, HD is a cost effective alternative to both IIV3 and IIV4 in seniors. Our conclusions were robust in the face of sensitivity analyses.
Keywords
Related Topics
Life Sciences Immunology and Microbiology Immunology
Preview
Expected cost effectiveness of high-dose trivalent influenza vaccine in US seniors
Authors
, , , ,